Mar 31 2020 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety View
Mar 24 2020 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development View
Mar 09 2020 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development View
Feb 25 2020 Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference View
Jan 10 2020 Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer View
Dec 20 2019 Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool View
Dec 09 2019 Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares View
